Christopher Hite - 11 Feb 2026 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: EVP & Vice Chairman
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite
Issuer symbol: RPRX
Transactions as of: 11 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 13 Feb 2026, 16:02:51 UTC
Previous filing: 07 Nov 2025
Next filing: 09 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hite Christopher	EVP & Vice Chairman	C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK	/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite	13 Feb 2026	0001814238

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPRX	Class A Ordinary Shares	Award	$0	+26,626	+4%	$0.000000	685,136	11 Feb 2026	By SCH Investment Partners LLC	F1
holding	RPRX	Class A Ordinary Shares						70,000	11 Feb 2026	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,238,789 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.